1. Home
  2. ONC vs JBL Comparison

ONC vs JBL Comparison

Compare ONC & JBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • JBL
  • Stock Information
  • Founded
  • ONC 2010
  • JBL 1966
  • Country
  • ONC Switzerland
  • JBL United States
  • Employees
  • ONC N/A
  • JBL N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • JBL Electrical Products
  • Sector
  • ONC Health Care
  • JBL Technology
  • Exchange
  • ONC Nasdaq
  • JBL Nasdaq
  • Market Cap
  • ONC 26.9B
  • JBL 23.4B
  • IPO Year
  • ONC N/A
  • JBL 1993
  • Fundamental
  • Price
  • ONC $250.30
  • JBL $222.00
  • Analyst Decision
  • ONC Strong Buy
  • JBL Strong Buy
  • Analyst Count
  • ONC 9
  • JBL 8
  • Target Price
  • ONC $325.56
  • JBL $217.50
  • AVG Volume (30 Days)
  • ONC 345.1K
  • JBL 2.0M
  • Earning Date
  • ONC 08-06-2025
  • JBL 06-17-2025
  • Dividend Yield
  • ONC N/A
  • JBL 0.14%
  • EPS Growth
  • ONC N/A
  • JBL N/A
  • EPS
  • ONC N/A
  • JBL 5.11
  • Revenue
  • ONC $4,175,868,000.00
  • JBL $28,514,000,000.00
  • Revenue This Year
  • ONC $869.15
  • JBL N/A
  • Revenue Next Year
  • ONC $19.07
  • JBL $4.66
  • P/E Ratio
  • ONC N/A
  • JBL $43.41
  • Revenue Growth
  • ONC 51.16
  • JBL N/A
  • 52 Week Low
  • ONC $146.21
  • JBL $95.85
  • 52 Week High
  • ONC $287.88
  • JBL $227.54
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • JBL 78.59
  • Support Level
  • ONC N/A
  • JBL $219.72
  • Resistance Level
  • ONC N/A
  • JBL $227.50
  • Average True Range (ATR)
  • ONC 0.00
  • JBL 4.61
  • MACD
  • ONC 0.00
  • JBL -0.76
  • Stochastic Oscillator
  • ONC 0.00
  • JBL 78.05

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About JBL Jabil Inc.

Jabil Inc is a United States-based company engaged in providing manufacturing services and solutions. It provides comprehensive electronics design, production and product management services to companies in various industries and end markets.The Company derives its revenue from providing comprehensive electronics design, production and product management services. It operates in two segments. The Electronics Manufacturing Services (EMS) segment, which is the key revenue driver, is focused on leveraging IT, supply chain design and engineering, technologies largely centered on core electronics. The Diversified Manufacturing Services (DMS) segment is focused on providing engineering solutions, with an emphasis on material sciences, technologies, and healthcare.

Share on Social Networks: